Lawrence J. Hineline is SVP of Finance, CFO of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 0 shares of ITCI, which is worth approximately $0. The most recent transaction as insider was on Mar 11, 2024, when has been sold 10,121 shares (Common Stock) at a price of $66.55 per share, resulting in proceeds of $673,552. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Lawrence J. Hineline Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 11 2024
SELL
Open market or private sale
$673,552 $66.55 p/Share
10,121 Reduced 100.0%
0 Common Stock
Mar 10 2024
BUY
Exercise of conversion of derivative security
$574,164 $56.73 p/Share
10,121 Added 69.04%
4,539 Common Stock
Mar 07 2024
SELL
Open market or private sale
$874,591 $66.6 p/Share
13,132 Reduced 100.0%
0 Common Stock
Mar 06 2024
BUY
Exercise of conversion of derivative security
-
13,132 Added 50.0%
13,132 Common Stock
Feb 26 2024
SELL
Open market or private sale
$925,987 $69.43 p/Share
13,337 Reduced 100.0%
0 Common Stock
Feb 26 2024
BUY
Exercise of conversion of derivative security
$216,986 $36.89 p/Share
5,882 Added 50.0%
5,882 Common Stock
Feb 23 2024
BUY
Exercise of conversion of derivative security
-
7,455 Added 50.0%
7,455 Common Stock
Feb 02 2024
SELL
Open market or private sale
$749,037 $66.98 p/Share
11,183 Reduced 100.0%
0 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
11,183 Added 50.0%
11,183 Common Stock
Jun 14 2023
SELL
Open market or private sale
$5,258,300 $64.24 p/Share
81,854 Reduced 100.0%
0 Common Stock
Jun 14 2023
BUY
Exercise of conversion of derivative security
$3,503,351 $42.8 p/Share
81,854 Added 50.0%
81,854 Common Stock
Mar 13 2023
SELL
Open market or private sale
$248,733 $44.56 p/Share
5,582 Reduced 100.0%
0 Common Stock
Mar 10 2023
SELL
Open market or private sale
$671,002 $42.84 p/Share
15,663 Reduced 100.0%
0 Common Stock
Mar 10 2023
BUY
Exercise of conversion of derivative security
-
5,582 Added 50.0%
5,582 Common Stock
Mar 09 2023
BUY
Grant, award, or other acquisition
-
15,663 Added 50.0%
15,663 Common Stock
Feb 24 2023
SELL
Open market or private sale
$350,608 $47.03 p/Share
7,455 Reduced 100.0%
0 Common Stock
Feb 23 2023
BUY
Exercise of conversion of derivative security
-
7,455 Added 50.0%
7,455 Common Stock
Feb 21 2023
SELL
Open market or private sale
$501,786 $48.05 p/Share
10,443 Reduced 100.0%
0 Common Stock
Feb 18 2023
BUY
Exercise of conversion of derivative security
-
10,443 Added 50.0%
10,443 Common Stock
Feb 17 2023
SELL
Open market or private sale
$2,709,193 $50.2 p/Share
53,968 Reduced 100.0%
0 Common Stock
Feb 17 2023
BUY
Exercise of conversion of derivative security
$687,012 $12.73 p/Share
53,968 Added 50.0%
53,968 Common Stock
Sep 21 2022
SELL
Open market or private sale
$2,974,085 $45.64 p/Share
65,164 Reduced 100.0%
0 Common Stock
Sep 21 2022
BUY
Exercise of conversion of derivative security
$1,008,087 $15.47 p/Share
65,164 Added 50.0%
65,164 Common Stock
Feb 24 2022
SELL
Open market or private sale
$384,999 $51.65 p/Share
7,454 Reduced 100.0%
0 Common Stock
Feb 23 2022
BUY
Exercise of conversion of derivative security
-
7,454 Added 50.0%
7,454 Common Stock
LJH

Lawrence J. Hineline

SVP of Finance, CFO
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI